MoneyWorks4Me

Akums Drugs and Pharmaceuticals informs about annual report

19 Jun 2026 Evaluate
Akums Drugs and Pharmaceuticals has informed that the Company has sent a letter providing the web-link, including the exact path, where the Integrated Annual Report of the Company for the Financial Year 2025-26 is available, to those members who have not registered their e-mail ID’s with the Company/ MUFG Intime India (formerly known as Link Intime India) - Registrar and Transfer Agent Depositories (RTA)/ Depository Participants (DPs). A copy of the letter is enclosed as ‘Annexure - A’.

The above information is a part of company’s filings submitted to BSE.

Akums Drugs & Pharma Share Price

752.40 8.70 (1.17%)
19-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1898.00
Dr. Reddys Labs. 1171.00
Cipla 1416.00
Lupin 2220.00
Zydus Lifesciences 1105.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: